Retatrutide vs Tirzepatide: What the Research Compares

In plain English

This page compares retatrutide and tirzepatide — two weight-loss drug candidates made by the same company, Eli Lilly. Tirzepatide has been approved and is being used. Retatrutide is not yet approved and is still in large clinical trials. The main mechanistic difference: tirzepatide targets two hormone receptors (GLP-1 and GIP), while retatrutide adds a third (glucagon). In Phase 2 trials — which are different studies with different designs and populations — retatrutide at its highest dose showed a mean 24.2% body-weight reduction, while tirzepatide's Phase 3 trials showed roughly 22.5% at its highest dose. These numbers come from separate studies and cannot be directly compared without the head-to-head data, which a large Phase 3 trial is currently collecting. Retatrutide vs tirzepatide head-to-head results are not yet published.

Mechanism: the third receptor

Tirzepatide is a dual agonist at GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). It was the first approved molecule to combine these two incretin targets in a single injection, and its Phase 3 weight-loss results were the highest seen from an approved agent at the time of approval.

Retatrutide adds a third target: glucagon receptor (GCGR). Glucagon is the pancreatic hormone that raises blood sugar and, via its receptor, increases energy expenditure and drives hepatic lipid (liver-fat) metabolism. The addition of partial glucagon agonism is the pharmacological basis for retatrutide's added metabolic burden on adipose and liver tissue. Cryo-EM structural analysis confirmed simultaneous binding at all three receptors, at relative potency ~8.9× GIPR, ~0.4× GLP-1R, ~0.3× GCGR versus the endogenous hormones ^[3].

This third receptor is also the source of an additional safety signal not present with tirzepatide: dose-dependent heart-rate increase. The glucagon receptor drives cardiac chronotropy (heart-rate increase) via cAMP/PKA signaling in the sinoatrial node ^[1].

Phase 2 weight-loss figures: indirect comparison

Direct head-to-head data comparing retatrutide vs tirzepatide have not been published. The following numbers come from separate trials with separate designs, populations, and durations — they are not a controlled comparison:

Retatrutide (Phase 2 obesity RCT, 48 weeks, 12 mg once weekly, n=338): mean body-weight change -24.2% versus -2.1% placebo ^[1].

Tirzepatide (Phase 3 SURMOUNT-1, 72 weeks, 15 mg once weekly, ~2500 participants): mean body-weight change approximately -22.5% versus placebo at 72 weeks.

Numbers diverge partly because the studies were different lengths (48 vs 72 weeks), different trial phases (2 vs 3), and different populations. Retatrutide's Phase 2 was not powered as a comparative trial; neither was SURMOUNT-1. A 2024 comparative review of seven GLP-1 receptor agonists and polyagonists positioned retatrutide as one of the highest-efficacy agents across the landscape ^[7]. A 2026 network meta-analysis ranked retatrutide highest for weight reduction among the glucagon receptor agonist class ^[11].

The head-to-head Phase 3 trial

NCT06662383 is an active-comparator Phase 3 RCT directly comparing retatrutide to tirzepatide in a randomized, double-blind design. This is the study that will produce genuine head-to-head data on weight loss, metabolic outcomes, and safety profile between the two compounds ^[8]. Results have not been published as of mid-2026.

This trial is the most important piece of forthcoming data for understanding how retatrutide vs tirzepatide actually compares in controlled conditions. Until it reports, indirect inferences from separate trials carry significant limitations.

Safety profile comparison

Both compounds share a GI adverse event profile — nausea, vomiting, diarrhea, constipation — from the GLP-1 receptor arm. The overlap is expected mechanistically.

Retatrutide adds a safety signal specific to glucagon receptor activation: dose-dependent heart-rate increase, peaking around week 24 in Phase 2 ^[1]. Tirzepatide does not produce the same magnitude of heart-rate increase in its approved-dose clinical data. A dedicated cardiovascular outcomes trial for retatrutide (NCT06383390) is ongoing; the CV safety profile at scale is unknown.

Both compounds reduce lean mass in addition to fat mass during rapid weight loss. A 2025 Lancet Diabetes & Endocrinology body-composition analysis confirmed retatrutide reduces lean mass alongside fat; adequate protein intake and resistance exercise are discussed in clinical literature as mitigating practices.

In the retatrutide vs tirzepatide Phase 3 trial (NCT06662383), adverse-event profiles will be compared directly for the first time ^[8].

Approval status

Tirzepatide is FDA-approved for type 2 diabetes and obesity. Retatrutide is investigational, with no regulatory approval anywhere as of mid-2026. This is the most consequential practical difference between the two compounds for anyone seeking access: tirzepatide can be prescribed; retatrutide cannot. The retatrutide availability section covers what access through clinical trials looks like.